Therapy of chronic myelogenous leukaemia with interferons. Cancer Surv 1989;8(4):793-8
Date
01/01/1989Pubmed ID
2701727Scopus ID
2-s2.0-0024956532 (requires institutional sign-in at Scopus site) 5 CitationsAbstract
Therapy of Philadelphia positive chronic myelogenous leukaemia (CML Ph1) with alpha interferon (IFN-alpha) resulted in a high frequency of haematological remissions. Effective suppression of the malignant Ph1 clone and concomitant partial or complete restoration of normal haemopoiesis is reproducibly noted in a proportion (30%-50%) of the patients. This and the low incidence of blast crisis underscore the profound effect this therapy has on the disease. Marked heterogeneity in the response to IFN-alpha was noted as well, and sensitivity or resistance to interferon was phenotypically indistinguishable. Studies of the IFN-resistant disease failed to disclose alteration in IFN receptors or in IFN-inducible genes and are suggestive, therefore, of a limited alteration in IFN-induced intracellular pathways.
Author List
Talpaz M, Kurzrock R, Kantarjian H, Gutterman JAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
HumansIn Vitro Techniques
Interferon Type I
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Remission Induction